Full-Time

District Manager

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

Compensation Overview

$148k - $222k/yr

Virginia, USA + 2 more

More locations: North Carolina, USA | United States

In Person

Must reside in East Coast district; 60-70% travel (overnight travel) required.

Category
Sales & Account Management (1)
Requirements
  • Minimum of a Bachelor’s degree and 3+ years pharmaceutical or healthcare product sales management experience required. However, a combination of experience and/or education will be taken into consideration.
  • Demonstrated leadership, motivational, and management skills required.
  • Prior successful pharmaceutical or healthcare sales management District Manager experience, medical devices, or other healthcare products sales experience preferred.
  • Ability to travel 60-70% (will include overnight travel).
  • Must reside in district geography.
  • Must possess a valid Driver's License and an acceptable driving record.
  • Authorization and ability to drive a Company leased vehicle or authorized rental vehicle.
  • Proficiency in speaking, comprehending, reading and writing English is required.
Responsibilities
  • Develop, enhance and increase district sales performance to meet or exceed annual Company sales and market share objectives. Ensure corporate sales and marketing direction is fully executed within a geographic area. Implement the district sales strategy (or business plan) to be executed through the team.
  • Develop and maintain solid customer relationships with key executives, decision influencers and decision makers as appropriate. Respond to the needs of the customer in a timely and professional manner. Conduct account reviews for key customers as required. Monitor product usage to determine growth and/or decrease in purchasing patterns. Update contract information as required.
  • Provide regular, candid and timely feedback to the district sales representatives and documents appropriately. Act early to identify performance challenges or deficiencies and creates plans to appropriately address performance gaps. Work closely with Sales Director and HR to guide all disciplinary actions up to and including terminations.
  • Analyze and evaluate the performance of the team as well as sales figures and territory data for geography. Track and reinforce measures of sales force effectiveness (e.g. reach and frequency; adherence to strategy; tactical implementation; proper use of funds, systems and tools).
  • Recruit and retain top talent applicants to ensure all positions are filled. Apply appropriate coaching styles to each direct report that motivates high performance and ensures accountability. Counsel and coach direct reports to maximize their performance and continue their professional development.
  • Perform all Company business in compliance with all applicable Company policies and procedures. Apply appropriate measures to ensure that sales representatives also are in compliance with all applicable company policies and procedures. Demonstrate high ethical and professional standards with all business contacts in order to maintain the Company's excellent reputation within the medical and pharmaceutical community.
  • Communicate candidly with Sales Director and direct reports. Ensure an open communication environment for direct reports. Serve as a focal point for the compilation and exchange of "Best Practices" across the district. Serve as communication liaison with home office and district to include the proactive identification and resolution of issues.
  • Possess ability to assess organizational change management needs and apply appropriate tools to manage change impact within respective organizational groups to ensure successful implementation.
  • Create a high-performing team environment which values continued professional development and personal accountability. Eliminate barriers and foster a solution-oriented winning vision throughout the district. Exhibit both a long-term, strategic view of the business with an acute focus on driving immediate results.
  • Exercise fiscal control on allocated operating budgets. Take direction from Regional Director regarding marketing, standards, etc. and ensure it is cascaded and followed within sales representative teams.
  • Perform other duties as assigned.
Desired Qualifications
  • Prior successful pharmaceutical or healthcare sales management District Manager experience, medical devices, or other healthcare products sales experience preferred.

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hits $3.52B, up 8.1%, driven by Greater China demand.
  • Projects 5-6% revenue CAGR through 2030 with $11B cash for deployments.
  • UBS upgrades to Buy with $18 target on Inpefa launches and cost savings.

What critics are saying

  • FDA Indore warning letter slashes stock 15% on February 27, 2025.
  • Pfizer biosimilar captures 35% EU Lipitor share, cutting $1.2B sales.
  • FTC probes Mylan pay-for-delay deals, imposing $2B fine by 2028.

What makes Viatris unique

  • Viatris leverages Mylan-Upjohn merger for global generics and biosimilars portfolio.
  • Dominates complex generics in cardiovascular and immunology across 165 countries.
  • Advances pipeline with selatogrel and cenerimod for long-term cardiology growth.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Viatris who can refer or advise you

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.